Skip to content Skip to sidebar Skip to footer

Widget HTML #1

Home / health / healthcare and medicine / hearing / hearing loss / medicine and healthcare

Universal CCMV Screening Identifies Newborns at Risk for Hearing Loss

By Newby

The Importance of Universal Screening for Congenital Cytomegalovirus

A recent study has highlighted the critical role of universal screening programs in identifying congenital cytomegalovirus (CMV) cases that could lead to hearing loss. According to the findings, one-third of CMV-related hearing loss cases would go undetected without such screening initiatives. This research was published in the November issue of Otolaryngology–Head and Neck Surgery.

The study, led by Celine Richard, M.D., Ph.D., from the University of Tennessee Health Science Center in Memphis, focused on the audiological outcomes of CMV-positive newborns who were identified through universal screening. The analysis involved patients who were tested for congenital CMV using saliva polymerase chain reaction (PCR) between March 2016 and May 2024.

During the study period, researchers identified 247 CMV-positive newborns, with 134 being male. Out of these, 31.17% showed symptoms at birth. Among the symptomatic group, 16 infants were diagnosed with sensorineural hearing loss (SNHL). Specifically, 12 had bilateral SNHL (BHL), while four had unilateral SNHL (UNHL). Additionally, late-onset UNHL was observed in three symptomatic patients.

In the asymptomatic group, four infants developed UNHL and one developed BHL within their first year of life. The study also looked into treatment outcomes. Fifty-eight patients received valganciclovir, an antiviral medication. Among those who eventually developed SNHL, five out of 10 treated patients experienced worsening or no improvement in their hearing. In contrast, 10 out of 14 untreated cases showed deterioration in hearing or no improvement, with only two remaining stable.

Compared to infants with normal hearing, those with SNHL had higher rates of microcephaly and intracranial calcifications. However, there were no differences in urine CMV viral load at birth between the groups.

Treatment and Intervention Options

Nine patients in the study received cochlear implants, with seven receiving bilateral implants and one receiving a unilateral implant. Additionally, four patients were provided with hearing aids, three of which were bilateral and one unilateral.

Maria A. Carrillo-Marquez, M.D., another researcher from the University of Tennessee Health Science Center, emphasized the importance of universal screening in identifying babies at risk for hearing loss who might otherwise be overlooked. She stated that screening based solely on symptoms or standard newborn hearing tests may not be sufficient to detect all cases.

Key Findings and Implications

The study underscores several important points:

  • Universal screening is essential for detecting CMV-related hearing loss in newborns.
  • Symptomatic and asymptomatic cases can both lead to hearing loss, highlighting the need for comprehensive screening.
  • Early intervention plays a crucial role in managing hearing loss and improving long-term outcomes.
  • Treatment options, such as valganciclovir, can help manage the condition, but outcomes vary depending on the timing and type of treatment.
  • Long-term monitoring is necessary for infants who show signs of hearing loss, as some cases may develop later.

These findings reinforce the necessity of implementing and maintaining universal CMV screening programs to ensure that all at-risk infants receive timely diagnosis and appropriate care. By doing so, healthcare providers can significantly improve the quality of life for children affected by CMV-related hearing loss.